Small study but clinical. I don't even know if it could be called phase 1, but at least on humans.
The study, published in Cell Reports Medicine, focuses on a new treatment combining pembrolizumab with standard chemotherapy to treat small cell bladder cancer and small cell/neuroendocrine prostate cancer. Small cell carcinomas are aggressive and have a low survival rate. This new combination therapy resulted in 43% of patients experiencing disease regression and showed increased survival rates. The study was conducted on 15 patients, and further research is needed to confirm the findings. The combination treatment was well-tolerated with no reported side effects.
New cancer treatment immuno therapy combined with guadecitabine in lung, breast, prostate bowel cancer makes cancer visible to immune sys
Metastasis Directed Therapy (MDT) is here to stay for Oligometastatic Patients !!! Part(1) SABR/SBRT